Core Insights - JD Health and Eli Lilly China have signed a strategic cooperation agreement to integrate quality medical resources and digital services for chronic disease management, focusing on obesity, diabetes, and alopecia [1][2] - Eli Lilly, a leading global pharmaceutical company with nearly 150 years of history, has made significant advancements in various fields, including diabetes and obesity, benefiting millions of patients worldwide [1] - The partnership aims to create a comprehensive management model that combines drug accessibility, health education, and digital services, enhancing patient trust and access to high-quality medications and healthcare services [1][2] Company Collaboration - JD Health will leverage its supply chain system to ensure stable direct supply of treatment products, supported by professional cold chain logistics for efficient and safe nationwide delivery [2] - The collaboration will include the establishment of a disease education section to improve patient awareness and self-management capabilities, along with online consultation and follow-up services through JD Internet Hospital [2] - Both companies will develop specialized tools and educational resources for healthcare professionals to enhance their diagnostic and management capabilities [2] Product Offerings - Eli Lilly has 25 products available for sale on JD Health, including the innovative drug Mounjaro (tirzepatide injection), which has gained significant attention since its launch on the platform [1] - The recent introduction of the multi-dose prefilled pen for Mounjaro provides patients with a more flexible and convenient medication option, enriching the treatment experience [1]

Core Viewpoint - Novo Nordisk continues to enhance its investment in China, focusing on a comprehensive industry chain strategy to better serve Chinese patients, with a mission to combat serious chronic diseases [3][4]. Group 1: Investment and Strategy - Novo Nordisk has introduced 22 innovative drugs and 11 innovative injection devices in China, addressing diabetes, obesity, and rare diseases, helping over 41 million patients by the end of 2024 [3]. - The company emphasizes a full industry chain layout, which includes commercial operations, production, and research and development [3]. Group 2: Innovation and Collaboration - At the China International Supply Chain Promotion Expo, Novo Nordisk announced new partnerships with local collaborators and launched a digital chronic disease management model, integrating online and offline resources [4]. - The company is collaborating with major internet platforms like Tencent Health, JD Health, Ping An Health, and Alibaba Health to build a digital ecosystem for chronic disease management [4]. Group 3: Sustainability Initiatives - Novo Nordisk aims for net-zero emissions across its entire value chain by 2045 and has initiated a three-year environmental management plan focusing on waste management and carbon reduction [5]. - The company has signed a multi-party agreement with leading firms in the medical field to utilize renewable energy in China, promoting green electricity transformation in the pharmaceutical industry [5].